BlackRock’s Fennec Pharmaceuticals FENC Stock Holding History

BlackRock’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.6M	Buy	1,727,069 +358,893	+26%	+$2.93M	﹤0.01%	3310
2026 Q1	$8.41M	Buy	1,368,176 +133,899	+11%	+$1.03M	﹤0.01%	3607
2025 Q4	$9.5M	Buy	1,234,277 +22,471	+2%	+$184K	﹤0.01%	3503
2025 Q3	$11.3M	Sell	1,211,806 -14,631	-1%	-$127K	﹤0.01%	3391
2025 Q2	$10.2M	Sell	1,226,437 -23,851	-2%	-$163K	﹤0.01%	3411
2025 Q1	$7.61M	Buy	1,250,288 +23,956	+2%	+$154K	﹤0.01%	3459
2024 Q4	$7.75M	Sell	1,226,332 -3,145	-0.3%	-$16.1K	﹤0.01%	3547
2024 Q3	$6.15M	Buy	1,229,477 +42,235	+4%	+$244K	﹤0.01%	3623
2024 Q2	$7.25M	Buy	1,187,242 +259,776	+28%	+$2.16M	﹤0.01%	3548
2024 Q1	$10.3M	Sell	927,466 -7,125	-0.8%	-$71.5K	﹤0.01%	3336
2023 Q4	$10.5M	Buy	934,591 +89,550	+11%	+$742K	﹤0.01%	3375
2023 Q3	$6.35M	Buy	845,041 +14,922	+2%	+$121K	﹤0.01%	3569
2023 Q2	$7.33M	Buy	830,119 +778,481	+1,508%	+$6.47M	﹤0.01%	3563
2023 Q1	$430K	Buy	51,638 +1,094	+2%	+$10.1K	﹤0.01%	4564
2022 Q4	$485K	Buy	50,544 +1,177	+2%	+$10.4K	﹤0.01%	4611
2022 Q3	$399K	Sell	49,367 -2,002	-4%	-$13.7K	﹤0.01%	4790
2022 Q2	$287K	Sell	51,369 -3,970	-7%	-$23K	﹤0.01%	4941
2022 Q1	$310K	Sell	55,339 -2,160	-4%	-$10.9K	﹤0.01%	5003
2021 Q4	$253K	Buy	57,499 +178	+0.3%	+$1.32K	﹤0.01%	5055
2021 Q3	$541K	Sell	57,321 -5,166	-8%	-$38.8K	﹤0.01%	4737
2021 Q2	$455K	Sell	62,487 -1,070,282	-94%	-$7.14M	﹤0.01%	4716
2021 Q1	$7.04M	Buy	1,132,769 +25,565	+2%	+$192K	﹤0.01%	3780
2020 Q4	$8.25M	Buy	1,107,204 +32,171	+3%	+$245K	﹤0.01%	3469
2020 Q3	$6.51M	Buy	1,075,033 +5,772	+0.5%	+$40.7K	﹤0.01%	3460
2020 Q2	$8.93M	Buy	1,069,261 +1,035,798	+3,095%	+$7.7M	﹤0.01%	3248
2020 Q1	$199K	Sell	33,463 -1,147	-3%	-$7.48K	﹤0.01%	4228
2019 Q4	$224K	Sell	34,610 -362	-1%	-$1.95K	﹤0.01%	4302
2019 Q3	$168K	Sell	34,972 -1,316	-4%	-$5.81K	﹤0.01%	4350
2019 Q2	$145K	Sell	36,288 -503,491	-93%	-$2.13M	﹤0.01%	4414
2019 Q1	$2.62M	Sell	539,779 -22,437	-4%	-$148K	﹤0.01%	3611
2018 Q4	$3.59M	Buy	562,216 +2,429	+0.4%	+$17K	﹤0.01%	3495
2018 Q3	$4.59M	Buy	559,787 +4,743	+0.9%	+$44K	﹤0.01%	3523
2018 Q2	$5.79M	Buy	+555,044	New	+$6.58M	﹤0.01%	3460

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

BlackRock's FENC Position: Q2 2026 in Review

BlackRock increased its Fennec Pharmaceuticals (FENC) stake by 26% in Q2 2026, buying an estimated $2.93M and bringing the position to 1,727,069 shares worth $18.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3310.

BlackRock first reported a position in FENC in Q2 2018 and has held it in 33 quarters since. 104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

BlackRock held 1,727,069 shares of Fennec Pharmaceuticals worth $18.6M as of Q2 2026.
BlackRock bought 358,893 Fennec Pharmaceuticals shares in Q2 2026, an estimated $2.93M.
Fennec Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3310 holding.
BlackRock first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.